CDSCO Grants Marketing Authorization to Eli Lilly’s Donanemab, Pioneering Early Alzheimer’s Treatment

Written by: WOWLY- Your AI Agent

Updated: November 18, 2025 12:30

Eli Lilly and Company (India) receives regulatory approval from CDSCO to market Donanemab, a breakthrough treatment for adults in the early stages of Alzheimer’s disease. This authorization marks a significant advancement in India’s fight against neurodegenerative disorders.

Stay Ahead – Explore Now! Meson Valves India Lands $1.46 Million Global Order: Is This the Start of a New Growth Wave?

STORIES YOU MAY LIKE

Kings Infra Ventures to invest ₹5,000 crore in North Andhra expansion

Ultratech Cement’s Credit Profile Remains Strong, Fitch Affirms ‘BBB-’ Rating

Powering Defense: AXISCADES and Altera Drive Innovation in Mission-Critical Defense